Cardio Round-up: Thrombotic Complications in COVID-19; Work Stress Increases PAD Risk; and More

This week’s Round-up features two updates for COVID-19, an update about how work-related stress increases the risk for peripheral artery disease, and a look at apixaban in patients with atrial fibrillation and chronic kidney disease.

Treating and Preventing Thromboembolic Complications in Patients with COVID-19

“Worldwide, COVID-19 is being treated as a primary pulmonary disease,” said Edwin J.R. van Beek, MD, PhD, director at Edinburgh Imaging, Queens Medical Research Institute, at the University of Edinburgh, UK, said in a press release about this study published in Radiology. “From the analysis of all available current medical, laboratory and imaging data on COVID-19, it became clear that symptoms and diagnostic tests could not be explained by impaired pulmonary ventilation alone.”

https://www.docwirenews.com/docwire-pick/cardiology-picks/covid-19-patients-imaging-workup-thromboembolic-complications/

–

Work Stress Increases the Odds for Hospitalization with Peripheral Artery Disease

Authors for this paper looked at 11 prospective cohort studies (conducted in Finland, Sweden, Denmark, and the UK) measuring self-reported job strain (high demands and low control) and compared them with hospital records of PAD between 1985 and 2008. The authors then used Cox regression to look at the link between PAD and job strain in each cohort study. The analysis sample included more than 139,000 (n=139,132) participants with no previous history of hospitalization for PAD.

https://www.docwirenews.com/docwire-pick/cardiology-picks/stress-from-work-increased-risk-hospitalization-pad/

–

Apixaban Shows Improved Bleeding Status vs. Warfarin in AFib Patients with CKD

“Compared with the general population, patients with advanced chronic kidney disease have a >10-fold higher burden of atrial fibrillation,” the authors wrote in their paper. “Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this population.” The research team for this study published in Circulation enrolled 269 patients with AFib and advanced chronic kidney disease from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation(ARISTOTLE) trial and compared the safety of apixaban with that of warfarin

https://www.docwirenews.com/docwire-pick/cardiology-picks/apixaban-chronic-kidney-disease-atrial-fibrillation-afib-reduced-bleeding/

–

ACE Inhibitors and ARBs in Hypertensive Patients with COVID-19

The authors of this JAMA Cardiology paper noted that “the use of ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is common treatment in cardiovascular disorders, including hypertension, and data regarding the association of these drugs with ACE2 levels are conflicting.” Patients hospitalized with COVID-19 infections at the Central Hospital of Wuhan, China between January 15 and March 15 were retrospectively reviewed.

https://www.docwirenews.com/docwire-pick/cardiology-picks/do-aceis-arbs-affect-severity-mortality-risk-in-hospitalized-covid-19-patients-with-hypertension/